Noopept ® is one of many unique peptide nootropics that have been extensively studied in Russia, though until recently they were largely unknown in Western countries. From 1985 until 2006 there have been 76 studies published that focused on different applications of Noopept ® for treating various conditions in humans. In 2006, Noopept ® successfully finished the third phase of clinical trials and was approved as an OTC pharmaceutical. Since then, it is produced in one of the Pharmstandard factories and is available in all Russian pharmacies.
Noopept Background – Noopept is a synthetic racetam molecules structurally similar to both Piracetam (seen as the basic racetam structure) as well as similarly structured to an endogenous dipeptide in the brain known as cycloprolylglycine (the amino acids proline and glycine in a cyclical configuration). Noopept itself appears to have bioactivity as does its metabolism into cycloprolylglycine (with Noopept sometimes being seen as a cycloprolylglycine pro-drug) and the overall spectrum of effects in animals and the one currently accessible study in humans suggesting very similar effects to that of Piracetam except occurring at a slightly higher potency and at a lower oral dose. Positive Effects – It holds much promise for patients with Alzheimer’s disease. When looking at the benefits, which require more human data, there is a general neuroprotective effect that appears to occur in all tested states of cognitive ailment (excitotoxicity, ischemia, oxidative stress, toxin stress, anticholinergics, physical trauma, etc.) but there is no evidence to support a cognitive enhancing effect of Noopept in otherwise healthy humans or animals. There is theoretically a cognitive enhancing effect (as it is noted, somewhat, with Piracetam although low in magnitude) and has mechanisms that should result in enhanced cognition in otherwise healthy persons (neurotropic factor enhancement) but this is yet to be explored. Side Effects – The one human study using Noopept (10mg taken twice a day) suggests that it is well tolerated for up to 56 days. Dosage – The recommended oral intake is between 10 and 30mg, which is from the manufacturer of Noopept for the purposes of treating cerebrovascular and posttraumatic cognitive deficiency. Optimum human dose for cognitive enhancement is not currently known. Misc. – Relative to Piracetam, Noopept is known to be taken at a much smaller oral dose (10-30mg daily, relative to Piracetam at 4800mg) and is claimed to have a subtle psychostimulatory effect. Conclusion – Further studies are needed to investigate its potential in cognitive enhancement
References http://examine.com/supplements/Noopept/ http://www.ncbi.nlm.nih.gov/pubmed/19240853 https://www.ncbi.nlm.nih.gov/pubmed/23156084 https://www.ncbi.nlm.nih.gov/pubmed/24555225
Noopept 50 Tabl. [10mg/tab]
- Brand: OTHER
- Product Code: Noopept 50 Tabl. [10mg/tab]
- Availability: Out Of Stock
- Ex Tax: $35.00